Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1Optic Neuritis 1Neuromyelitis Optica 1Myelitis, Transverse 1Myasthenia Gravis 1Demyelinating Diseases 1

Interventions

rozanolixizumab 5zilucoplan 4eculizumab 4efgartigimod alfa 3Rituximab 2Prednisone 2Amifampridine 2thymoglobulin 1satralizumab 1rhoA GTP-Binding Protein 1ravulizumab 1iscalimab 1inebilizumab 1gamma-Globulins 1Thymectomy 1Sugars 1Steroids 1Sodium Chloride 1Robotic Surgical Procedures 1Prednisolone 1Methylprednisolone 1Methotrexate 1Mesna 1Hizentra 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Fluid Therapy 1Cyclophosphamide 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Myasthenia Gravis × ravulizumab × Clear all
NCT03920293 2024-05-28

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3 Completed
175 enrolled 15 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡